A new study has found a strong link between exposure to Agent Orange and the development of myelodysplastic syndromes (MDS), a group of bone marrow cancers affecting blood cell production.
Researchers discovered that veterans exposed to Agent Orange are twice as likely to carry high-risk genetic abnormalities. Mutations in genes such as TET2, SRSF2, and KRAS were more common, suggesting the chemical may trigger long-term genetic damage that leads to cancer decades later. The disease also appears more aggressive in exposed individuals, who are diagnosed at a younger age and are about 80% more likely to progress to acute leukemia within two years.
The study also highlighted disparities, showing that Black veterans were nearly three times more likely to report exposure compared to white veterans.
These findings could have major implications for veterans’ healthcare. Currently, the U.S. Department of Veterans Affairs does not officially classify MDS as a condition linked to Agent Orange exposure. This research provides strong evidence that may support policy changes, potentially allowing more veterans to qualify for healthcare coverage and disability benefits related to their illness.